Navigation Links
Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1
Date:5/4/2011

OKLAHOMA CITY, May 4, 2011 /PRNewswire/ -- Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.  

The placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose study of SelG1 will enroll approximately 30 healthy subjects. This study will evaluate the safety and pharmacology of SelG1 prior to advancement into a Phase II trial in patients with sickle cell disease.

"This Phase I study represents the first step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and we are excited to initiate the clinical development of this novel compound," said Dr. Scott Rollins, Selexys President and CEO. "This Phase I trial represents a key milestone for Selexys as we transition from a preclinical to a clinical development stage biopharmaceutical company."

In 2008, Selexys received orphan-drug designation for SelG1 from the Food and Drug Administration Office of Orphan Products Development for the treatment of vasoocclusive crisis, a severe and painful complication of sickle cell disease. Orphan drug designation is awarded to therapeutics with the potential for safe and effective treatment diagnosis or prevention of rare diseases and disorders that affect fewer than 200,000 people.

About SelG1

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. In preclinical studies, inhibition of P-selectin has been shown to effectively prevent vasoocclusion by blocking critical cell-cell interactions that drive this process. Therapeutic blockade of P-selectin may therefore reduce vasoocclusion and subsequent crises in patients with sickle cell disease.

"SelG1 represents a first-in-class therapeutic approach for the treatment of sickle cell disease
'/>"/>

SOURCE Selexys Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aires Pharmaceuticals Appoints Edwin L. Parsley as Chief Medical Officer
2. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
3. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
8. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
9. Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill Lynch Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report ... Devices in US$ Million by the following Product ... Nanotechnology Coatings. The report provides separate comprehensive analytics ...
(Date:8/20/2014)... PHOENIX , Aug. 20, 2014 ... cutting-edge next-generation sequencing and proteomic diagnostics and biomarker ... a collaboration with TESARO, Inc.  Paradigm will use ... samples from clinical trials to better predict which ... TSR-011.  This may lead to more successful clinical trial ...
(Date:8/20/2014)... ApolloDx™ today announced it will unveil and ... event at the company,s office in Salt ... The event, which will start at 10:00 a.m., will ... .    "We believe our mobile diagnostic ... , Co-Founder and Managing Partner of ApolloDx. In addition ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Jan. 23, 2012   South Florida Radiation Oncology, LLC (SFRO) ... with Mevion Medical Systems to purchase the MEVION S250 ... develop the first proton therapy treatment center in West ... targeted to begin in 2013. South ...
... (B. Braun), a leader in infusion therapy and pain management, ... approval for 2g Cefazolin for Injection USP and Dextrose ... The FDA approval makes B. Braun the first ... and other healthcare settings where it is a frequently prescribed ...
Cached Medicine Technology:South Florida Radiation Oncology to Develop Proton Therapy Center 2B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 2B. Braun Becomes the First to Deliver FDA-Approved 2g Cefazolin 3
(Date:8/20/2014)... University of Adelaide researchers have discovered that the immune ... which is a major reason why sufferers have ongoing issues ... kind in the world could also help to explain ... , Irritable bowel syndrome (IBS) affects up to 10% of ... all of them involve unexplained gut pain, which often has ...
(Date:8/20/2014)... The time to deploy Ebola vaccines is now, ... is now, according to a commentary being published early ... . The authors from Yale School of Public ... dissemination of the current Ebola outbreak represent a public ... current efforts. Several Ebola vaccines have been developed in ...
(Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
(Date:8/20/2014)... 20, 2014 (HealthDay News) -- Loss of brain cells ... why many seniors have trouble falling and staying asleep, ... disruption can be especially severe and often results in ... The investigators analyzed data from the Rush Memory and ... at age 65 and are being followed until death, ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... cells grow may help doctors diagnose and treat the most ... have found that the deadliest skin cancers occur most often ... long history of sun exposure. These lesions also grow ... cell growth -- called "high mitotic rate" -- is ...
Breaking Medicine News(10 mins):Health News:Pain treatments less effective for those with irritable bowel 2Health News:News from Annals of Internal Medicine 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3
... workers increased more for small businesses than for large ones ... a significant number of small employers to abandon the benefit, ... , Small businesses (those with 25 or fewer employees) saw ... percent during the study period -- significantly more than the ...
... at Ralphs Pharmacies Throughout Southern California, LOS ANGELES, ... pharmacy customers generic drugs for $4 per prescription at,its ... apply to hundreds of generic drugs prescribed for,30-day supplies ... stores,throughout Southern California. A list of the participating pharmacies ...
... with Visit from Legendary Recording Artist Chaka Khan, ... California Science,Center welcomed the 1-millionth visitor to BODY ... has been a record-breaking run for BODY WORLDS,at ... Grammy,Award-winning recording artist Chaka Khan and a group ...
... between father,s, but not mother,s, weight and elevated enzymes ... fathers had early-onset obesity are at increased risk for ... U.S. study. , Researchers evaluated 1,732 children, average age ... long-term study of families in Framingham, Mass. The researchers ...
... Ky., April 3, 2008 Targeted mass,media ... high,sensation-seeking, impulsive decision-making young adults to adopt ... by the Department of,Communication at the University ... of Mental Health., Past public health ...
... 2008 Facial trauma,is a too frequent occurrence ... Carolyn McCarthy (D-N.Y.) hopes to raise,awareness of this ... (H. Res. 1062) to designate April 2008 as ... ), An estimated 5 million teeth are ...
Cached Medicine News:Health News:Study finds economic burden of health insurance increasing for small employers 2Health News:Ralphs Introduces $4 Generic Drugs 2Health News:California Science Center Welcomes 1-Millionth BODY WORLDS Visitor 2Health News:Dads' Early-Onset Obesity Linked to Liver Disease in Kids 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 3Health News:Oral and Maxillofacial Surgeons Raise Awareness About the Importance of Facial Protection 2
... Powerful ventilated floor-standing centrifuge. Mobile ... rotors, large choice of accessories, analog ... detection & shutdown (JOUAN patented pendulum ... current and temperature limitation, rugged motor, ...
... the infinity-corrected optical system for improved visibility ... taken this one step further with the ... the capability of a fluorescence illuminator for ... and video monitoring. The CKX41 is routinely ...
Display for prescription eyewear clip-on sunglasses. The Clipper clip-on sits right in front of, and just below, its host frame and will accommodate both the normal brow wire and the new, lower wire ...
Counter top frosted acrylic 4 frame display....
Medicine Products: